Study of Pemetrexed for Second-Line Pancreas Cancer
Status:
Terminated
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
This study is for patients with pancreatic cancer that has grown and/or spread after having
previously received the standard chemotherapy drug called gemcitabine.
In this study a drug called pemetrexed is being tested. This drug is approved by the FDA for
use in lung cancer and mesothelioma. The purpose of this study is to see if pemetrexed keeps
pancreas cancer that has grown and/or spread after gemcitabine from growing. Subjects will
receive pemetrexed IV once every 21 days until disease progression or unacceptable side
effects occur.